SIS3 HCl
(Synonyms: SIS3 盐酸盐) 目录号 : GC17191SIS3HCl 是一种有效的选择性 Smad3 抑制剂,对 Smad3 磷酸化的 IC50 为 3 μM。
Cas No.:521984-48-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 3 μM
SIS3 HCI is an inhibitor of Smad3.
The receptor-associated Smads, such as Smad2 and Smad3, directly interact with activated TGF-receptor type I. Smads form heteromeric complexes with Smad4, which is a common mediator for all Smad pathways.
In vitro: In the reporter assay, it was found that the increased luciferase activity of p3TP-lux could be abrogated by the SIS3 HCI treatment in a dosedependent manner. Immunoprecipitation revealed SIS3 HCI attenuated the TGF-1-induced phosphorylation of Smad3 and interaction of Smad3 with Smad4. Whereas, SIS3 did not affect the phosphorylation of Smad2. In addition, it was found that SIS3 HCI attenuated the effects of TGF-1 by reducing the transcriptional activity. SIS3 HCI could also inhibit the myofibroblast differentiation of fibroblasts by TGF-1. Moreover, SIS3 HCI diminished the constitutive phosphorylation of Smad3 completely [1].
In vivo: Animal study showed that, in Tie2-Cre;Loxp-EGFP mice, AGEs could induce EndoMT. Immunoprecipitation and Western blotting showed that Smad3 could be activated by AGEs but was inhibited by SIS3 HCI in both MMECs and in STZ-induced diabetic nephropathy. Furthermore, confocal microscopy and real-time PCR showed that SIS3 HCI could abrogate EndoMT, reduce renal fibrosis, as well as retard nephropathy progression [2].
Clinical trial: Up to now, SIS3 HCI is still in the preclinical development stage.
IC50: 3 μM
SIS3 HCI 是一种Smad3抑制剂。
受体相关Smads,如Smad2和Smad3,直接与活化的TGF-受体I相互作用。Smads与Smad4形成异源二聚体,后者是所有Smad通路的共同介质。
体外:在报告基因实验中,发现SIS3 HCI治疗可剂量依赖性地消除p3TP-lux的增强荧光素活性。免疫共沉淀发现,SIS3 HCI减弱了TGF-1诱导的Smad3磷酸化和Smad3与Smad4的相互作用。而SIS3并不影响Smad2的磷酸化。此外,研究发现SIS3 HCI通过减少转录活性来减轻TGF-1的作用。SIS3 HCI还可以通过TGF-1抑制成肌成纤维细胞的分化。此外,SIS3 HCI完全减弱了Smad3的非瘤细胞的构成性磷酸化[1]。
体内:动物研究表明,对Tie2-Cre;Loxp-EGFP小鼠的研究发现,AGEs可以诱导内皮间质转化。免疫共沉淀和Western blotting显示Smad3可以被AGEs激活,但在MMECs和STZ诱导的糖尿病性肾病中被SIS3 HCI抑制。此外,共聚焦显微镜和实时PCR显示,SIS3 HCI可以消除内皮间质转化,减少肾脏纤维化,并减缓肾病的进展[2]。
临床试验:截至目前,SIS3 HCI仍处于临床前开发阶段。
References:
[1] Jinnin M et al. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607.
[2] Li J et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes.2010 Oct;59(10):2612-24.
Cas No. | 521984-48-5 | SDF | |
别名 | SIS3 盐酸盐 | ||
化学名 | (E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one hydrochloride | ||
Canonical SMILES | CN1C(C2=CC=CC=C2)=C(C3=C1N=CC=C3)/C([H])=C([H])/C(N4CCC5=CC(OC)=C(OC)C=C5C4)=O.Cl | ||
分子式 | C28H28ClN3O3 | 分子量 | 489.99 |
溶解度 | ≥ 49 mg/mL in DMSO, ≥ 11 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0409 mL | 10.2043 mL | 20.4086 mL |
5 mM | 0.4082 mL | 2.0409 mL | 4.0817 mL |
10 mM | 0.2041 mL | 1.0204 mL | 2.0409 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。